Full US approval of Gilead’s Tecartus was the only positive decision last month.
ApexOnco Front Page
Recent articles
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
BeOne's degrader BG-60366 appears to have been discontinued.
Daraxonrasib scores a plenary session late-breaker.
